Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.65 |
| ▸ | FNTB | P49356 | 12/20 | 0.65 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.65 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690483 | 0.92 | BTN3A1 (0.54) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL22235275 | 0.92 | BTN3A1 (0.54) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL29456761 | 0.90 | FNTA (0.52) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL29500461 | 0.89 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL396770 | 0.89 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL19658104 | 0.88 | FNTA (0.78) | FNTAFNTBPGGT1B | |
| Biphenyl SCHEMBL6700610 | 0.81 | FNTA (0.48) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL6689625 | 0.80 | ALOX15 (0.60) | FNTAFNTBGGPS1 | |
| SCHEMBL31591259 | 0.80 | FNTA (0.66) | FNTAFNTBPGGT1B | |
| SCHEMBL25669649 | 0.80 | FNTA (0.62) | FNTAFNTBPGGT1BGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082155-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-11926644-B2 | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives | CORNELL UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023225102-A1 | CONTINUOUS FLOW METHODS FOR PRODUCING MANNOSE-1-PHOSPHATE, POLYMORPHS OF MANNOSE-1-PHOSPHATE, AND COMPOSITIONS AND USES RELATED THERETO | GLYCOMINE, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-2314686-B2 | Cells producing antibody compositions | KYOWA KIRIN CO LTD (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4194551-A1 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | Alteogen, Inc. (KR) | 2023-06-14 | — | — | EP | disclosed |
| US-20230174963-A1 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | ALTEOGEN INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230001020-A1 | SELECTIVE EXPANSION OF GENE-TARGETED CELLS | BAYLOR COLLEGE OF MEDICINE (US) | 2023-01-05 | — | — | US | disclosed |
| US-11530233-B2 | Beta-nicotinate ester nucleotides and processes for preparing same | CORNELL UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115427562-A | Method for preparing recombinant hyaluronidase | 阿特根公司 | 2022-12-02 | — | — | CN | disclosed |
| US-5659015-A | FOR ENHANCING SERUM LIFETIME OF PROTEIN CONJUGATES; ENHANCING DRUG DELIVERY | GENZYME CORP (US) | 1997-08-19 | — | — | US | disclosed |
| US-5272070-A | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-12-21 | — | — | US | disclosed |
| US-5241072-A | Complexing | GENZYNE CORPORATION | 1993-08-31 | — | — | US | disclosed |
| US-5218092-A | Stability | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0535052-A1 | OLIGOSACCHARIDE OXAZOLINES, OLIGOSACCHARIDE CONJUGATES AND METHODS OF PREPARATION THEREOF | GENZYME CORPORATION (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991018911-A2 | OLIGOSACCHARIDE OXAZOLINES, OLIGOSACCHARIDE CONJUGATES AND METHODS OF PREPARATION THEREOF | GENZYME CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1991018106-A1 | MODIFIED ANTIBODIES | CENTRAL BLOOD LABORATORIES AUTHORITY (GB) | 1991-11-28 | — | — | WO | disclosed |
| EP-0400075-A4 | ENHANCEMENT OF THE THERAPEUTIC PROPERTIES OF GLYCOPROTEIN | — | 1991-07-03 | — | — | EP | disclosed |
| EP-0400075-A1 | ENHANCEMENT OF THE THERAPEUTIC PROPERTIES OF GLYCOPROTEIN | GENZYME CORPORATION (US) | 1990-12-05 | — | — | EP | disclosed |
| WO-1989007641-A1 | ENHANCEMENT OF THE THERAPEUTIC PROPERTIES OF GLYCOPROTEIN | GENZYME CORPORATION (US) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530233-B2 | Beta-nicotinate ester nucleotides and processes for preparing same | NAPRT, NAMPT, NNT | FNTA 133/4885FNTB 56/4885PGGT1B 446/4885 |
| US-11926644-B2 | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives | NQO1, NME4, NQO2 | FNTA 1110/4885FNTB 1179/4885PGGT1B 1991/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | FNTA 137/4885FNTB 613/4885PGGT1B 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.